20879-18-9

Basic information

• Product Name: (+)-Dichloroisoproterenol
• CAS NO: 20879-18-9
• Molecular Weight: 248.152
• Mol File: 20879-18-9.mol

Chemical Properties

• CAS DataBase Reference: (+)-Dichloroisoproterenol(CAS DataBase Reference)
• NIST Chemistry Reference: (+)-Dichloroisoproterenol(20879-18-9)
• EPA Substance Registry System: (+)-Dichloroisoproterenol(20879-18-9)

Safety Data

• Hazardous Substances Data: 20879-18-9(Hazardous Substances Data)

Upstream product

• 59-61-0 dichloroisoproterenol 
• 52909-94-1 2-(3,4-dichlorophenyl)oxirane 
• 75-31-0 isopropylamine 
• 390405-95-5 (S)-2-bromo-1-(3,4-dichloro-phenyl)ethanol 
• 256474-26-7 (S)-(+)-(3,4-Dichlorophenyl)oxirane 
• 2632-10-2 2-bromo-1-(3,4-dichlorophenyl)ethanone 
• 50-00-0 formaldehyd 

Downstream Products

• 390406-77-6 1H-benzoimidazole-4-carboxylic acid (4-{3-[2-(3,4-dichloro-phenyl)-2-hydroxy-ethyl]-3-isopropyl-ureido}-phenyl)-amide 
• 390406-74-3 3-(4-Aminomethyl-phenyl)-1-[(S)-2-(3,4-dichloro-phenyl)-2-hydroxy-ethyl]-1-isopropyl-urea 
• 390406-71-0 (4-{3-[2-(3,4-dichloro-phenyl)-2-hydroxy-ethyl]-3-isopropyl-ureido}-benzyl)-carbamic acid tert-butyl ester 
• 390404-98-5 [2-(4-{3-[2-(3,4-dichloro-phenyl)-2-hydroxy-ethyl]-3-isopropyl-ureido}-phenyl)-ethyl]-carbamic acid tert-butyl ester 
• 390406-02-7 (4-{3-[2-(3,4-dichloro-phenyl)-2-hydroxy-ethyl]-3-isopropyl-ureido}-phenyl)-carbamic acid tert-butyl ester 

Relevant articles and documents

Asymmetric synthesis of β-adrenergic blockers through multistep one-pot transformations involving in situ chiral organocatalyst formation

Two birds one stone: A new atom-economical one-pot approach to enantioselective chiral drug synthesis, involving in situ multistep organocatalyst formation and the application of the reaction for multistep sequential synthesis of β-adrenergic blockers is disclosed (see scheme).

One-pot route to β-adrenergic blockers via enantioselective organocatalysed epoxidation of terminal alkenes as a key step

A convenient and environmentally attractive one-pot two-step process for the synthesis of β-adrenergic blockers via Shi's organocatalytic epoxidation of terminal alkenes and subsequent aminolysis reaction of epoxides with isopropylamine under mild reaction conditions has been developed. This journal is the Partner Organisations 2014.

Discovery and initial structure-activity relationships of trisubstituted ureas as thrombin receptor (PAR-1) antagonists

Thrombin is the most potent agonist of platelet activation, and its effects are predominantly mediated by platelet thrombin receptors. Therefore, antagonists of the thrombin receptor have potential utility for the treatment of thrombotic disorders. Screening of combinatorial libraries revealed 2 to be a potent antagonist of the thrombin receptor. Modifications of this structure produced 11k, which inhibits thrombin receptor stimulated secretion and aggregation of platelets.

A two-step asymmetric synthesis of (R)-monoaryl epoxides using a chiral oxathiane as a recoverable reagent: Application to the preparation of (R)-β-adrenergic compounds

It is shown that chiral oxathiane 1 is a recoverable and efficient chiral auxiliary which provides, in two steps, (R)-monoaryl epoxides in high enantiomeric purity (98% R and 92% R according to the solvent used). (R)-β-Adrenergic compounds (R)-(-)-DCI and